sembragiline: Clinical Trials

7 trials of sembragiline, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 4 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 23Completed 3

Follow sembragiline: new trials by email Literature Review of sembragiline trials Research Report on sembragiline

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
Placebo RO4602522, RO4602522, moxifloxacin - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche2032014-04-012016-11-02
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
RO4602522, Placebo, Donepezil - Alzheimer's Disease
Phase 2CompletedHoffmann-La Roche5422012-10-242017-05-30
A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
11C-L-deprenyl-D2, RO4602522 - Healthy Volunteer, Alzheimer's Disease
Phase 1CompletedHoffmann-La Roche172012-09-012016-11-02
A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
RO4602522, ketoconazole - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche342012-07-012016-11-02
A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers
RO4602522 - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche62012-06-012016-11-02
Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.
EVT 302, Placebo, EVT 302 plus open label Nicotine replacement - Smoking Cessation
Phase 2CompletedEvotec Neurosciences GmbH4002008-08-012009-05-29
Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes
EVT 302, 10 mg, placebo, Nicotine replacement therapy (NRT) - Smoking Cessation
Phase 2CompletedEvotec Neurosciences GmbH902008-02-012008-06-17

Conditions studied

Alzheimer Disease (2)  ·  Smoking Cessation (2)

Sponsors

Hoffmann-La Roche (5)  ·  Evotec Neurosciences GmbH (2)

Countries

Germany (3)  ·  Netherlands (2)  ·  Sweden (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Italy (1)  ·  Poland (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Alla Radicke, MD (1)  ·  H D Stahl, MD, PhD (1)

Results publications

PMID 28550255, PMID 37230961